Andrew Polson's Biography

Andrew Polson, Principal Scientist, Genentech

Dr Andrew Polson is Principal Scientist (Technology), Translational Oncology at Genentech, USA where he has 14 years of experience. Dr Polson joined Genentech in 2002 after finishing his post-doctoral work in virology at UCSF. Dr Polson completed his Ph.D. in Biochemistry from University of Utah in the year 1995.Since Joining Genentech he has been working on developing antibody-drug conjugates for the treatment of cancer. His lab works on the development of antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, for the treatment of cancer. Their goal is to provide a means to deliver chemotherapy by targeting the drug to neoplastic cells.
Dr Polson is a Biomedical research scientist with a diverse skill set and over twelve years of professional experience. He is a thought leader in the field of large-molecule biologics with a unique perspective on antibody drug conjugate (ADC) design and development. Dr Polson Initiated and led preclinical research programs for multiple ADCs; played a key role in filing two investigational new drug applications for novel ADCs with continued involvement with progress through clinical trials. He is also Project leader for multi-disciplinary teams tasked with the development of novel therapeutics.
Dr Polson plays a leadership role in external collaborations to develop new linker-drug technologies for antibody drug conjugate therapies.
He has extensive managerial experience with supervising research associates and Ph.D. scientists. He has successful record of contribution to scientific literature establishing key concepts in preclinical ADC development. He is an inventor on multiple ADC-related patents.
Dr Polson has 7 publications and received 2 awards/ honours i.e. American Cancer Society Postdoctoral Fellowship – 1998-2000 and National Cancer Institute Research Service Award – 1990-1993